| Birjitender Singh, MD | |
|
3406 Davenport Ave, Saginaw, MI 48602 | |
| (989) 790-3450 | |
| (989) 401-6201 |
| Full Name | Birjitender Singh |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 34 Years |
| Location | 3406 Davenport Ave, Saginaw, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124131719 | NPI | - | NPPES |
| 1124131719 | Medicaid | MI | |
| 5194972 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4301083758 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| First State Hospice Care Inc | Saginaw, MI | Hospice |
| Covenant Medical Center | Saginaw, MI | Hospital |
| Ascension St Mary's Hospital | Saginaw, MI | Hospital |
| Entity Name | Satnam Medical Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811132616 PECOS PAC ID: 5294898375 Enrollment ID: O20090115000525 |
News Archive
Since the 2009 discovery that energy-burning brown fat can be active in adults, research has raced ahead to understand this tissue and exploit it to treat the epidemic of obesity. Active brown fat also may assist in directly easing the burden of diabetes and related metabolic diseases by lowering the levels of glucose and fatty acids in the bloodstream. But progress in studying human brown fat often has been slowed by difficulties in obtaining and studying samples of the human cells that develop into brown fat.
New research has found that drug-resistant strains of tuberculosis are just as likely to be transmitted between people as drug-sensitive TB, which could make drug-resistant forms of the disease "highly prevalent in the next few decades," the Australian Associated Press/Sydney Morning Herald reports (Rose, 8/11).
A study in the Journal of Biological Chemistry identifies a new therapeutic approach to treat prostate cancer. Conducted at Cincinnati Children's Hospital Medical Center, the research shows that expression of the FoxM1 protein is essential for prostate cancer to develop in mouse models. The study appears in the journal's Aug. 2 edition.
Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Birjitender Singh, MD 3406 Davenport Avenue, Saginaw, MI 48602 Ph: (989) 790-3450 | Birjitender Singh, MD 3406 Davenport Ave, Saginaw, MI 48602 Ph: (989) 790-3450 |
News Archive
Since the 2009 discovery that energy-burning brown fat can be active in adults, research has raced ahead to understand this tissue and exploit it to treat the epidemic of obesity. Active brown fat also may assist in directly easing the burden of diabetes and related metabolic diseases by lowering the levels of glucose and fatty acids in the bloodstream. But progress in studying human brown fat often has been slowed by difficulties in obtaining and studying samples of the human cells that develop into brown fat.
New research has found that drug-resistant strains of tuberculosis are just as likely to be transmitted between people as drug-sensitive TB, which could make drug-resistant forms of the disease "highly prevalent in the next few decades," the Australian Associated Press/Sydney Morning Herald reports (Rose, 8/11).
A study in the Journal of Biological Chemistry identifies a new therapeutic approach to treat prostate cancer. Conducted at Cincinnati Children's Hospital Medical Center, the research shows that expression of the FoxM1 protein is essential for prostate cancer to develop in mouse models. The study appears in the journal's Aug. 2 edition.
Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.
› Verified 2 days ago
Jerry Xavier, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Houghton Ave, 1100 Internal Medicine, Saginaw, MI 48602 Phone: 989-583-5826 | |
Ray Peter Mangulabnan, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3170 Hallmark Ct, Saginaw, MI 48603 Phone: 989-790-1275 Fax: 989-249-4199 | |
Shafia Beg, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1000 Houghton Ave, Saginaw, MI 48602 Phone: 989-583-6800 | |
Dr. Natasa Petreska, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 Houghton Ave, Saginaw, MI 48602 Phone: 989-746-7500 | |
Dr. Manoj Sharma, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4884 Berl Dr, Saginaw, MI 48604 Phone: 989-497-9395 Fax: 989-497-9599 | |
Minoo Khetarpal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1320 N Michigan Ave, Suite 4, Saginaw, MI 48602 Phone: 989-755-5500 Fax: 989-755-7860 | |
Christine I Rohr, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Houghton Ave, Saginaw, MI 48602 Phone: 989-583-6800 Fax: 989-583-6915 |